Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by StockNews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday.

Several other research analysts also recently commented on the stock. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,097.25.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $829.43 on Monday. The firm has a 50 day moving average of $1,043.57 and a 200-day moving average of $1,039.92. Regeneron Pharmaceuticals has a 12 month low of $783.57 and a 12 month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $91.44 billion, a PE ratio of 20.53, a PEG ratio of 2.90 and a beta of 0.15.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.48% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of REGN. Norden Group LLC grew its stake in Regeneron Pharmaceuticals by 48.1% during the first quarter. Norden Group LLC now owns 388 shares of the biopharmaceutical company’s stock worth $373,000 after purchasing an additional 126 shares during the period. Quent Capital LLC increased its stake in shares of Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 19 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $32,264,000. BI Asset Management Fondsmaeglerselskab A S lifted its position in shares of Regeneron Pharmaceuticals by 6.3% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 4,779 shares of the biopharmaceutical company’s stock valued at $4,600,000 after acquiring an additional 285 shares during the period. Finally, Commerce Bank boosted its stake in Regeneron Pharmaceuticals by 0.5% during the first quarter. Commerce Bank now owns 6,246 shares of the biopharmaceutical company’s stock worth $6,012,000 after acquiring an additional 29 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.